

ENDEXX CORPORATION

INTERIM QUARTER REPORT

For the periods ended March 31, 2016 and 2015

5855 Surrey Drive
P.O. Box 4317
Cave Creek, AZ, 85331
(Address of principal executive offices)

480-595-6900
(Issuer's Telephone Number, Including Area Code)

Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results:

This unaudited report contains forward-looking statements. The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management's plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "will" and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings and financial results.

We caution that the factors described herein and other factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Item 1. Name of the issuer and its predecessors (if any)

From 2005 to Present: Endexx Corporation
From 2002-2005: Panamed Corporation
From 1997-2002: Micron Solutions, Inc.

Item 2. Address of the issuer's principal executive offices

Company Headquarters
5855 Surrey Drive
Cave Creek, AZ. 85331

Mailing Address:

P.O. Box 4317
Cave Creek, AZ, 85327

Phone: (480) 595-6900
Fax: (480)-626-1696

Email: endexx@endexx.com
Website: www.endexx.com

Investor Relations Contact
Todd Davis
480-595-6900
PO Box 4317
Cave Creek, AZ. 85331
Todd.Davis@endexx.com

Item 3. Security Information

- Trading Symbol: EDXC
- The exact title and class of securities outstanding: Common stock and preferred stock are authorized and outstanding
- CUSIP Number: 29259K 10 2
- Par or Stated Value: Common Stock: $0.0001 par value per share.
  Preferred Stock: $0.01 par value per share.
- Total Shares Authorized: Common Stock: 1,000,000,000 shares
  Preferred Stock: 10,000,000 shares
- Total Shares Outstanding:
  Common Stock: 238,544,425 shares as of March 31, 2016
  Preferred Stock: 7,296,000 shares as of March 31, 2016
- The name and address of the transfer agent:

First American Stock Transfer
4747N. 7th St., #170
Phoenix, AZ 85104

First American Stock Transfer is registered under the Securities Exchange Act of 1934 and is regulated by the Securities and Exchange Commission.

There are no restrictions on the transfer of the Company's securities; and the Company has not been subject to any trading suspension orders issued by the SEC in the past 12 months.

No stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization is either currently anticipated or has occurred within the past 12 months:

Item 4. Issuance History

List of securities offerings and shares issued for services in the past two years:

The following events resulted in changes in total shares outstanding by the issuer in the past two year period ending on the last day of the issuer's most recent fiscal year:

During the year ended September 30, 2015 the Company issued 16,151,740 shares of common stock.

On October 30, 2014, we issued 125,000 shares of our restricted common stock valued at $6,250 for payment for website domains ownership.

On January 27, 2015, we issued 20,000 shares of our restricted common stock for the purchase of CanCan packaging products for our inventory with a value of $2,000.

On January 27, 2015, the Company issued 1,500,000 shares of our common stock as payment to

an unrelated individual for payment of consulting on our Investor and Public Relations, valued at $65,850, and is reflected in the accompanying statement of operations in *"Consulting fees."*

During the period ended March 31, 2015, we issued 1,085,000 shares of our restricted common stock to four persons for an aggregate amount of $30,000 net of offering costs of none.

On March 20, 2015, we issued 4,000,000 shares of our restricted common stock to purchase a wholly owned subsidiary, CBD Health Solutions, LLC (CBD). This is a company dedicated to the manufacturing and distribution of hemp based CBD-rich nutraceuticals ("Cannsumables").

On March 31, 2015, we issued 3,300,000 shares of our restricted common stock for financing costs of a previous acquisition transaction and is reflected in the accompanying statement of operations in *"Interest Expense."*

During the period ended June 30, 2015, we issued 521,740 shares of our restricted common stock to one person for an aggregate amount $12,000 net of offering costs of none.

During the period ended September 30, 2015, the Company settled an aggregate amount of $193,500 of its accounts payable to an unrelated vendor for Public Relations for 4,300,000 shares of our restricted common shares valued at $0.045 per share, with no offering costs.

During the period ended September 30, 2015, we issued 500,000 shares of our restricted common stock to one person for an aggregate amount $10,000 net of offering costs of none.

<u>During the period ended March 31, 2016 the Company issued 4,230,769 shares of common stock.</u>

On October 14, 2015, the Company issued 384,615 shares of our restricted common stock for finder's fees for the private placement stock purchase dated October 14, 2015, these shares were valued at $5,000, and is reflected in the accompanying statement of operations in *"Consulting fees."*

On October 14, 2015, we issued 3,846,154 shares of our restricted common stock for an aggregate amount $50,000 net of offering costs of none for a private placement.

During the period ended March 31, 2016, we issued 7,496,630 shares of our restricted common stock for an aggregate amount $92,499 net of offering costs of none for a private placement.

On January 1, 2016, the Company issued 526,316 shares of our common stock valued at $10,000; as payment to an unrelated individual for payment of an outstanding accounts payable invoice of $5,000 and for cash received of $5,000.

On March 30, 2016, the Company issued 2,250,000 shares of our common stock as payment to an unrelated individual for payment of consulting on our wholesale retail sale vendors, valued at $39,060, and is reflected in the accompanying statement of operations in *"Consulting fees."*

Each of the above securities offerings or transactions was made by officers and directors of the issuer and was not a registered offering. The offerings relied upon an exemption under Regulation S or Rule 4(a)(2) of the Securities Act of 1933, as amended. The shares in these offerings or transactions were restricted (i.e., not freely tradable); and the certificates evidencing such shares contained a legend (1) stating that the shares have not been registered under the Securities Act of 1933, as amended, and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act of 1933, as amended.

Item 5. Financial information for the issuer’s most recent fiscal period.

The Company's unaudited financial statements for the periods ended March 31, 2016 and 2015 are attached hereto as part of the Company's Interim Quarter Report and filed herewith.

ENDEXX CORPORATION

TABLE OF CONTENTS

Part I	Financial Information	Page
Item 1.	Financial Statements	
	Unaudited Condensed Consolidated Balance Sheets for the period ended March 31, 2016 and for the year ended September 30, 2015	1
	Unaudited Condensed Consolidated Statements of Operations for the three and six months ended March 31, 2016 and 2015	2
	Unaudited Condensed Consolidated Statements of Stockholders' Equity for the period from October 1, 2014 through March 31, 2016	3
	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2016 and 2015	4
	Condensed Notes to Consolidated Financial Statements (unaudited)	5

Endexx Corporation
Unaudited
Consolidated Balance Sheets

	For the period ended March 31, 2016	For the year ended September 30, 2015
ASSETS		
Current Assets		
Total Cash on Hand	$ 26,569	$ 23,426
Accounts Receivable		
Accounts receivable	7,784	7,784
Inventory - dispense equipment, oils, and products	83,130	101,648
Prepaid Expenses	41,717	41,717
Total Current Assets	159,199	174,575
Fixed Assets		
Fixed Assets		
Computer/Office Equipment	13,213	13,213
Total Fixed Assets	13,213	13,213
Accum Depreciation/Amortization		
Accum Depr-Computer/Office Eq	(7,510)	(6,189)
Total Accum Depreciation/Amortization	(7,510)	(6,189)
Total Fixed Assets	5,703	7,024
Other Assets		
Investment - Website domains	6,250	6,250
Investment - CBHS LLC	400	400
Total Other Assets	6,650	6,650
TOTAL ASSETS	**$ 171,552**	**$ 188,249**
LIABILITIES & EQUITY		
Liabilities		
Current Liabilities		
Accounts Payable		
Accounts Payable	$ 658,920	$ 498,174
Total Accounts Payable	658,920	498,174
Other Current Liabilities		
License Fee Payable	54,600	54,600
Deferred Lease Revenue	10,260	10,260
Accrued Expenses	31,205	31,205
Payroll Liabilities		
Wages Payable	1,382,500	1,307,500
Payroll Taxes Payable	166,230	149,205
Total Payroll Payable	1,548,730	1,456,705
Payroll Liabilities - Other	4,779	4,779
Total Payroll Liabilities	1,553,509	1,461,484
Sales & Use Tax Payable		
VA Use Tax Payable	439	338
Total Sales & Use Tax Payable	439	338
S/T Notes Payable	52,154	31,393
Total Current Liabilities	2,361,087	2,087,454
Total Liabilities	2,361,087	2,087,454
Stockholders' Equity		
Preferred Stock Par Value $0.0001		
7,296,000 shares issued and outstanding, March 31, 2016 and September 30, 2015, respectively	730	730
Capital Stock, Par Value $0.0001		
238,544,425 and 227,862,478 shares issued and outstanding, March 31, 2016 and September 30, 2015, respectively	23,858	22,792
Additional Paid in Capital	8,735,076	8,589,583
Common Stock Receivable	-	-
Total Shareholder's Equity	8,759,664	8,613,105
Retained Earnings	(10,512,309)	(9,342,861)
Net Income	(436,891)	(1,169,448)
Total Equity	(2,189,536)	(1,899,205)
TOTAL LIABILITIES & EQUITY	**$ 171,552**	**$ 188,249**

Endexx Corporation
Unaudited
Consolidated Statements of Operations

	For the three months ended March 31,		For the six months ended March 31,	
	2016	2015	2016	2015
Ordinary Income/Expense				
Income				
Revenues	$ 45,851	$ 25,049	$ 111,590	$ 31,506
Total Revenues	45,851	25,049	111,590	31,506
Cost of Goods Sold				
Total Cost of Sales	48,704	34,022	108,569	34,079
Gross Profit	(2,852)	(8,973)	3,020	(2,573)
Expense				
Telephone and communications expe	3,040	1,176	5,457	2,007
Office Supplies Expense	7,054	3,071	13,683	6,302
Contract Labor				
Consulting fees	41,166	151,447	168,821	156,992
Consulting fees - Related Party	15,000	-	35,000	-
Total Consulting	56,166	151,447	203,821	156,992
Total Contract Labor	56,166	151,447	203,821	156,992
General & Adminsitrative				
Depreciation	661	311	1,321	581
Advertising and Promotion	18,515	4,446	34,210	6,811
Postage and Delivery	1,292	111	1,708	3,007
Insurance			-	6,273
Professional Fees				
Stock Agency/Transfer Fees	-	1,750	2,529	3,500
Legal Fees	7,294	80,616	10,630	95,662
Accounting	6,592	2,500	18,892	5,000
Total Legal-Prof Fees	13,886	84,866	32,051	104,162
Travel & Entertainment				
G&A - Airfare/Lodging	6,398	5,351	8,809	15,080
G&A - Meals & Entertainment	4,517	4,097	8,063	8,248
Total Travel & Entertainment	10,915	9,448	16,872	23,328
Total General & Adminsitrative	45,270	99,182	86,162	144,162
Payroll Expenses				
Salaries	37,500	37,500	75,000	75,000
Total Salaries & Wages	37,500	37,500	75,000	75,000
Payroll Taxes & Benefits				
Company payroll taxes	9,375	9,375	18,750	18,750
Total Payroll Taxes & Benefits	9,375	9,375	18,750	18,750
Total Payroll Expenses	46,875	46,875	93,750	93,750
Office Rent	4,500	6,600	10,481	14,735
Research and Development	370	25,110	17,650	69,579
Utilities				
Utilities - other	1,196	415	3,413	909
Internet	577	655	1,529	1,793
Total Utilities	1,773	1,070	4,942	2,702
Total Expense	165,048	334,531	435,946	490,227
Net Ordinary Income	(167,900)	(343,504)	(432,926)	(492,800)
Other (Income)/Expense				
Interest expense	-	270,990	3,965	270,993
Gain on Stock trading	-	-	-	(23,755)
Total Other (Income)/ Expenses	-	270,990	3,965	247,238
Net Income	**$ (167,900)**	**$ (614,494)**	**$ (436,891)**	**$ (740,040)**
NET (LOSS) PER SHARE - BASIC AND DILUT	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	221,740,738	221,740,738	232,093,247	221,740,738

ENDEXX CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT)

	Preferred Stock		Common Stock		Paid-in	Subscription	Common Stock	Accumulated	
	Shares	Amount	Shares	Amount	Capital	Receivable	Subscribed	(Deficit)	Total
Balances, September 30, 2014	7,296,000	$ 730	211,735,124	$ 21,177	$ 7,975,600	$ -	$ -	$ (9,342,861)	$ (1,345,355)
Shares issued for acquisition of website domains at $0.05 per share on October 30, 2014, net of offering costs	-	-	125,000	13	6,237	-	-	-	6,250
Shares issued for consulting services at $0.0439 per share on January 27, 2015	-	-	1,500,000	150	65,700	-	-	-	65,850
Shares issued for acquisition of CanCan Products at $0.10 per share on January 27, 2015, net of offering costs	-	-	20,000	2	1,998	-	-	-	2,000
Shares issued for cash in a private placement at $0.04 per share on January 27, 2015, net of no offering costs	-	-	125,000	13	4,987	-	-	-	5,000
Shares issued for cash in a private placement at $0.03125 per share on February 26, 2015, net of no offering costs	-	-	160,000	16	4,984	-	-	-	5,000
Shares issued for cash in a private placement at $0.025 per share on March 17, 2015, net of no offering costs	-	-	200,000	20	4,980	-	-	-	5,000
Shares issued for cash in a private placement at $0.025 per share on March 17, 2015, net of no offering costs	-	-	600,000	60	14,940	-	-	-	15,000
Shares issued for acquisition of CBHS LLC at $0.001 per share on March 20, 2015	-	-	4,000,000	400	-	-	-	-	400
Shares issued for financing services at $0.082 per share on March 31, 2015	-	-	3,300,000	330	270,270	-	-	-	270,600
Shares issued for settlement accounts payable at $0.045 per share on April 8, 2015, net of no offering costs	-	-	1,000,000	100	44,900.00	-	-	-	45,000
Shares issued for cash in a private placement at $0.03125 per share on April 17, 2015, net of no offering costs	-	-	800,000	80	24,920	-	-	-	25,000
Shares issued for cash in a private placement at $0.023 per share on June 26, 2015, net of no offering costs	-	-	521,740	52	11,948	(12,000)	-	-	0
Wire Transfer received for common stock receivable above July 2, 2015	-	-	-	-	-	12,000	-	-	12,000
Shares issued for cash in a private placement at $0.02 per share on July 27, 2015, net of no offering costs	-	-	500,000	50	9,950	-	-	-	10,000
Shares issued for settlement accounts payable at $0.045 per share on August 17, 2015, net of no offering costs	-	-	3,300,000	330	148,170.00	-	-	-	148,500
Net (loss) for the period								(1,169,448)	(1,169,448)
Balances, September 30, 2015	7,296,000	730	227,886,864	22,792	8,589,583	-	-	(10,512,309)	(1,899,203)
Shares issued for cash in a private placement at $0.013 per share on October 14, 2015, net of no offering costs	-	-	3,846,154	385	49,615	-	-	-	50,000
Shares issued for investor fees for private placement completed on October 14, 2015 at $0.013 per share on October 14, 2015	-	-	384,615	38	4,962	-	-	-	5,000

ENDEXX CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT)

	Preferred Stock		Common Stock		Paid-in	Subscription	Common Stock	Accumulated	
	Shares	Amount	Shares	Amount	Capital	Receivable	Subscribed	(Deficit)	Total
Shares issued for settlement accounts payable and cash at $0.0190 per share on January 1, 2016, net of no offering costs	-	-	526,316	53	9,947.37	-	-	-	10,000
Shares issued for cash in a private placement at $0.0110 per share on February 9, 2016, net of no offering costs	-	-	909,000	91	9,908	-	-	-	9,999
Shares issued for cash in a private placement at $0.0110 per share on February 26, 2016, net of no offering costs	-	-	1,363,636	136	14,864	-	-	-	15,000
Shares issued for cash in a private placement at $0.0160 per share on March 1, 2016, net of no offering costs	-	-	468,750	47	7,453	-	-	-	7,500
Shares issued for cash in a private placement at $0.0110 per share on March 7, 2016, net of no offering costs	-	-	909,090	91	9,909	-	-	-	10,000
Shares issued for consulting services at $0.0172 per share on March 30, 2016	-	-	450,000	45	7,695	-	-	-	7,740
Shares issued for consulting services at $0.0174 per share on March 30, 2016	-	-	1,800,000	180	31,140	-	-	-	31,320
Net (loss) for the period								(436,891)	(436,891)
Balances, March 31, 2016	7,296,000	$ 730	238,544,425	$ 23,857	$ 8,735,076	$ -	$ -	$ (10,949,200)	$ (2,189,534)

The accompanying notes are an integral part of these financial statements

ENDEXX CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the six months ended March 31,	
	2016	**2015**
OPERATING ACTIVITIES		
Net (loss)	$ (436,891)	$ (740,040)
Adjustments to reconcile net income (loss) to net cash used by operating activities:		
Stock issued for services	44,060	340,840
Depreciation and amortization	1,321	581
Changes in operating assets and liabilities:		
Prepaid expenses	-	130,183
Inventory	18,518	70,500
Accounts receivable	-	(19,323)
Accounts payable	165,748	(192,229)
Deferred lease revenue	-	10,260
Accrued liabilities	92,126	68,100
NET CASH (USED BY) OPERATING ACTIVITIES	(115,118)	(331,127)
INVESTING ACTIVITIES		
Cash invested in Dudad application	-	388
Cash invested in Dispense Labs	-	150,000
Cash invested in stock trading holdings	-	13,100
Purchase of property and equipment	-	(2,510)
NET CASH (USED BY) INVESTING ACTIVITIES	-	160,978
FINANCING ACTIVITIES		
Proceeds from sale of common stock	97,500	29,999
Proceeds from shareholder advances/ notes	20,761	141,480
Repayment of notes payable	-	(2,300)
NET CASH PROVIDED BY FINANCING ACTIVITIES	118,261	169,179
NET (DECREASE) IN CASH	3,143	(970)
CASH, BEGINNING OF PERIOD	23,426	5,893
CASH, END OF PERIOD	$ 26,569	$ 4,923
CASH PAID FOR INTEREST	$ -	$ -
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES		
Debt Converted to Common Stock		
Accounts payable	$ 5,000	$ -
Common stock	(5,000)	-
	$ -	$ -
Stock issued for purchase of assets		
Purchase of website domains	$ -	$ 6,250
Common stock	-	(6,250)
	$ -	$ -

SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS

ENDEXX, INC.
Condensed Notes to Consolidated Financial Statements
For the Periods Ended March 31, 2016 and 2015

As used in this annual report, the terms the "Company," "we," "our" and "us" refer to EDXC. This report should be read in conjunction with our annual report for the year ended September 30, 2015, including the unaudited consolidated financial statements and related notes included therein.

1. History of the Company and Summary of Significant Accounting Policies

History of the Company

In 2002, Panamed Corporation merged with the predecessor known as Micron Solutions, a lost stock services company. The company changed its name from Micron Solutions to Panamed in 2002, due to the merger.

From 2002-2005, the company operated as Panamed Corporation, a biotech service and licensing company. Panamed invested 1.2 million dollars into a biotech technology and conducted a therapeutic treatment program in Ivory Coast Africa, In October 2004, Panamed Corporation filed a Form 15-12g to be a non-reporting company at the demand of the SEC. This demand was followed by a request for an expedited trial in Los Angeles Federal Court. The contingency was that the SEC could not recommend to the Judge/Court a fine or punishment. Panamed was fined $5,000.00 USD and the case was settled in court by the Judge in December of 2012.

Panamed Corporation merged with Visual Board Books Inc. (VBB) in February 2005 through an all stock transaction and changed the consolidated company name to Endexx Corporation.

Currently, Endexx Corporation is a Nevada Corporation, with five wholly owned subsidiaries: Global Solaris Group LLC and Cann Can LLC, CBD Health Solutions LLC, Dispense Labs LLC and Greenleaf Consulting LLC. Endexx also has three separate divisions (M3Hub Technology, CBD Unlimited, and Project Canopy, an App Development Program). In June 2011, Endexx Corporation acquired Global Solaris Group LLC., an Arizona LLC that develops Solar and Renewable energy projects both in the United States and in the International markets. Endexx has invested $60,000 into Global Solaris Group in 2011-2012 and issued 12 million shares for that division valued at $1.2 million, and it has recently completed its first solar project.

During 2010 – 2013, Endexx has also invested in and is pursuing several different projects including:

Endexx invested $30,000 into Project Canopy in 2010.

Endexx issued 5 million shares of stock to buy and develop the APP known as DUDAD in December 2012, and has invested $111,930 in its development as of June 30, 2014.

Endexx has invested $80,000 cash in M3Hub, and has issued $1.0 million dollars in stock to purchase Dispense Labs LLC.

In February 2013, Endexx acquired Cann Can LLC., a vending solutions company, and invested $6,000 into Cann Can Labs in 2013.

Endexx issued 5 million shares to purchase Hayes Pharmacy compliance platform in February 2013. In December 2013, we rescinded this purchase and cancelled the 5 million shares originally issued, and we issued 300,000 shares for consulting services that were rendered by Hayes Pharmacy in conjunction with our business plan.

On August 6, 2014, we issued 2,700,000 shares of our restricted common stock to purchase a wholly owned subsidiary, Greenleaf Consulting. This is a business consulting firm in the medical marijuana industry, and provides consulting on state regulations, guidelines, and business plans.

On March 20, 2015, we issued 4,000,000 shares of our restricted common stock to purchase a wholly owned subsidiary, CBD Health Solutions, LLC (CBD). This is a company dedicated to the manufacturing and distribution of hemp based CBD-rich nutraceuticals (“Cannsumables”).

Nature of Business

The company has never been a shell corporation. The company operates presently as a Medical Marijuana Management and technology solutions provider, as a solar and renewable energy developer, and has a development stage company currently retooling its software as a service platform and developing Mobile Solution Apps. Endexx Corporation is the parent corporation. Through project Canopy and Visual Board Books, it can provide three Web enabled services that assist organizations with the complexities of document management and storage. The company's product primarily include Visual Board Books that provides an environment to create, deliver, edit, view, and review corporate data, as well as offers an interface to communicate and confer with approved parties; Endexx Document Management Suite, a suite of Document/data management tools, which are designed to enhance the handling, storage, and control of document; and Endexx Storage Application, which is a base module for offsite storage of files and photos that require backup in an offsite location. It's wholly owned subsidiary, Global Solaris Group LLC., is an integrator of Renewable Energy Services. Based in Sedona, Arizona, GLOBAL SOLARIS GROUP LLC is a full service Renewable Energy power provider and producer for public institutions, corporate clients and electric utilities.

Summary of Significant Accounting Policies

Basis of Accounting

The Company prepares its consolidated financial statements in conformity with generally accepted accounting principles in the United States of America. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these

estimates are reasonable and have been discussed with the Board of Directors; however, actual results could differ from those estimates.

Use of Estimates

The Company prepares its consolidated financial statements in conformity with generally accepted accounting principles in the United States of America. These principals require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these estimates are reasonable and have been discussed with the Board of Directors; however, actual results could differ from those estimates.

Principles of Consolidation

The consolidated financial statements include the accounts and operations of Endexx Corporation and its wholly owned subsidiaries, CBD Health Solutions, LLC, a Missouri LLC; Greenleaf Consulting LLC, a New Jersey LLC; Dispense Labs, LLC, a California LLC; and Global Solaris Group LLC and Cann Can LLC., both Arizona LLCs (collectively referred to as the "Company"). Accordingly, the assets and liabilities, and expenses of this company have been included in the accompanying consolidated financial statements, and intercompany transactions have been eliminated.

Development Stage Enterprise

At March 31, 2016 , Endexx's business operations had not fully developed and are dependent upon funding and therefore Endexx is considered a development stage enterprise. Endexx has also adopted early the FASB released ASU 2014-10 concerning our development stage enterprise financial statement presentation.

Financial Instruments

The Company's balance sheets include the following financial instruments: cash, accounts receivable, accounts payable and note payable and notes payable to stockholder. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying values of the note payable to stockholder approximates fair value based on borrowing rates currently available to the Company for instruments with similar terms and remaining maturities.

In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2008 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 *"Fair Value Measurements and Disclosures"* (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an

exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

• Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities

• Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts receivable, other current assets, accounts payable, accrued compensation and accrued expenses. The fair value of the Company' s notes payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value.

The Company applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company's financial statements.

As of March 31, 2016 and 2015, the fair values of the Company's financial instruments approximate their historical carrying amount.

Cash and Cash Equivalents

The majority of cash is maintained with a major financial institution in the United States. Generally, deposits may be redeemed on demand and, therefore, bear minimal risk. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are based on the straight-line method over the estimated useful lives of the related assets. When assets are retired or otherwise disposed of, the cost and accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in operations in the period realized.

Depreciation

Depreciation is computed on the straight-line method net of salvage value with useful lives as follows:

Computer equipment and software	3 - 5 years
Office furniture and equipment	5 - 7 years
Machinery and equipment	7 - 10 years
Leasehold improvements	lease term

Dividends

The Company has not adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown.

Liquidity

The Company anticipates that revenue or income for fiscal year 2016 may be limited, but based upon our historical data we expect to continue to show growth. The Company also expects to continue to incur substantial expenses relating to its marketing and sales efforts. As a result, the Company expects to incur losses over the next year unless it is able to realize additional revenues under any current or future agreements. The timing and amounts of such revenues, if any, cannot be predicted with certainty. Accordingly, results of operations for any period may be unrelated to the results of operations for any other period.

The Company will likely need to raise and is pursuing additional funds through strategic collaborations, public or private equity or debt financing, or other funding sources. This funding may not be available on acceptable terms, or at all, and may be dilutive to shareholder interests. If sufficient capital is not available, the Company may be required to delay, reduce the scope of or eliminate one or more of its product offerings, any of which could have a material adverse effect on its business. If the Company is not able to secure additional capital by the end of its fiscal year, it may be forced to terminate operations altogether in fiscal year 2016.

Stock Based Compensation

The Company follows FASB ASC 718-10 and values our employee stock based awards based on the grant-date fair value estimated in accordance with the provisions of FASB ASC 718-10. The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 718-10 and the conclusions reached in FASB ASC 505-10. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-10.

Research and development costs

Research and development costs are charged to expense as incurred and are included in operating expenses. Total research and development costs were $17,280 and $44,469 for the periods ended December 31, 2015 and 2014, respectively.

Advertising Costs

The costs of advertising are expensed as incurred. Advertising expenses are included in the Company's operating expenses. Advertising expense was $17,650 and $69,579 for the periods ended March 31, 2016 and 2015, respectively.

Income Taxes

The Company accounts for income taxes under the liability method. Deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purpose, referred to as temporary differences.

Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized.

Revenue Recognition

The Company recognizes revenue when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price if fixed or determinable, and collectability is reasonably assured.

Earnings (Loss) Per Common Share

The Company computes net loss per share in accordance with FASB ASC 260-10, "Earnings per Share". FASB ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding

(denominator) during the period. Diluted EPS gives effect to all potentially dilutive common shares outstanding during the period. Diluted EPS excludes all potentially dilutive shares if their effect is anti-dilutive. There are no potentially dilutive options or warrants from inception.

Impact of Recently Issued Accounting Pronouncements

Recent accounting standards that have been issued or proposed by the FASB or other standards setting bodies are not expected to have a material impact on our financial position, results of operations and cash flows.

Accounts Receivable

Accounts receivable are stated at face value, less an allowance for doubtful accounts. Abakan provides an allowance for doubtful accounts based on management's periodic review of accounts, including the delinquency of account balances. Accounts are considered delinquent when payments have not been received within the agreed upon terms, and are written off when management determines that collection is not probable. As of March 31, 2016 management has determined that no allowance for doubtful accounts is required.

General Accounting Policy for Contingencies

Certain conditions may exist which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company, or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they arise from guarantees, in which case the guarantees would be disclosed.

As of March 31, 2016 and 2015, the Company’s management believes that there are no outstanding legal proceedings which would have a material adverse effect on the financial position of the Company.

Subsequent Events

In accordance with ASC 855-10 "Subsequent Events", Endexx has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through the date the financial statements were issued (Note 7).

2. Going concern

Our financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have sustained operating losses since inception, which raises substantial doubt about the Company's ability to continue as a going concern.

As of March 31, 2016 we have a working capital deficit of $2,201,888, and accumulated deficit of $10,949,200. During the period ended March 31, 2016 we had a net loss of $436,891 and cash used by operating activities of $115,119. The Company's ability to continue in existence is dependent on its ability to develop additional sources of capital, and/or achieve profitable operations and positive cash flows. Management's plan is to aggressively pursue its present business plan. Since inception we have funded our operations through the issuance of common stock and related party loans and advances, and will seek additional debt or equity financing as required. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3. Notes Payable

During the period ended March 31, 2016, the Company received two short term loans for an aggregate amount of $9,000, from two un-related individuals. Both notes are payable upon demand, and are noninterest bearing and noncollateralized.

On December 17, 2015, the Company also entered into a third noninterest bearing, noncollateralized note payable for $50,000. The note is convertible into shares of our restricted common stock and has a financing fee payable calculated as fifteen percent of the gross profit of our CBD Unlimited product sales.

4. Stock Based Compensation

On January 27, 2015, the Company issued 1,500,000 shares of our common stock as payment to an unrelated individual for payment of consulting on our Investor and Public Relations, valued at $65,850, and is reflected in the accompanying statement of operations in *"Consulting fees."*

On October 14, 2015, the Company issued 384,615 shares of our restricted common stock for finder's fees for the private placement stock purchase dated October 14, 2015, these shares were valued at $5,000, and is reflected in the accompanying statement of operations in *"Consulting fees."*

On March 30, 2016, the Company issued 2,250,000 shares of our common stock as payment to an unrelated individual for payment of consulting on our wholesale retail sale vendors, valued at $39,060, and is reflected in the accompanying statement of operations in *"Consulting fees."*

Stock Issued for Domain names

On October 30, 2014, we issued 125,000 shares of our restricted common stock for certain domain names at a value of $6,250.

Stock Issued for CanCan Product Inventory

On January 27, 2015, we issued 20,000 shares of our restricted common stock for the purchase of CanCan packaging products for our inventory with a value of $2,000.

5. Stockholder's Equity

Stock Shares – Authorized

The Company has 1,000,000,000 common shares authorized at a par value of $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.01 per share. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all the directors of the Company. There is currently only one designated class of preferred shares, "A." The holders of the preferred stock shall have such rights, preferences and privileges as may be determined by the Board of Director's prior to the issuance of such shares. The preferred stock may be issued in such series as are designated by the Board of Director's and the Board of Director's may fix the number of authorized shares of preferred stock for each series and the rights, preferences, and privileges of each series of preferred stock.

As of the periods March 31, 2016 and September 30, 2015 there were 238,544,425 and 227,862,478 shares of our common stock issued and outstanding, respectively. As of the periods ended March 31, 2016 and September 30, 2015 there were 7,296,000 shares of our preferred stock issued and outstanding, respectively.

Common Shares – Issued and Outstanding

In the period ended March 31, 2016, the Company had the following shares transactions in addition to the issuances discussed elsewhere.

During the period ended March 31, 2016, we issued 7,496,630 shares of our restricted common stock for an aggregate amount $92,499 net of offering costs of none for a private placement.

On January 1, 2016, the Company issued 526,316 shares of our common stock valued at $10,000; as payment to an unrelated individual for payment of an outstanding accounts payable invoice of $5,000 and for cash received of $5,000.

In the period ended September 30, 2015, the Company had the following shares transactions in addition to the issuances discussed elsewhere.

On October 30, 2014, we issued 125,000 shares of our restricted common stock for certain domain names at a value of $6,250.

On January 27, 2015, we issued 20,000 shares of our restricted common stock for the purchase of CanCan packaging products for our inventory with a value of $2,000.

On January 27, 2015, the Company issued 1,500,000 shares of our common stock as payment to an unrelated individual for payment of consulting on our Investor and Public Relations, valued at $65,850, and is reflected in the accompanying statement of operations in *"Consulting fees."*

During the period ended September 30, 2015, we issued 2,906,740 shares of our restricted common stock for an aggregate amount $65,000 net of offering costs of none.

On March 20, 2015, we issued 4,000,000 shares of our restricted common stock to purchase a wholly owned subsidiary, CBD Health Solutions, LLC (CBD). This is a company dedicated to the manufacturing and distribution of hemp based CBD-rich nutraceuticals ("Cannsumables").

On March 31, 2015, we issued 3,300,000 shares of our restricted common stock valued at $270,600 for financing costs of a previous acquisition transaction and is reflected in the accompanying statement of operations in *"Interest Expense."*

On April 8, 2015, the Company issued 1,000,000 shares of our common stock as payment to an unrelated individual for payment of an outstanding accounts payable invoice.

6. Commitments

Consulting Agreement

On October 20, 2014, Greenleaf Consulting entered into a consulting agreement to provide services to an unrelated individual in regards to the individual medical marijuana business in the state of New York for an initial period of twelve months, and shall automatically renew for subsequent four month terms unless terminated by either party with a 15 day notice. Greenleaf Consulting will be paid $200 per hour of billable time, and shall be reimbursed for reasonable related expenses.

On May 1, 2015, The Company entered into an amendment of a previous consulting agreement with a related party, to perform the duties of Chief Operating Officer and Vice President. The terms of the previous agreement remain in force except for the following: we will provide a monthly salary of $5,000 effective June 1, 2015, until April 30, 2018. We also agreed to issue 6,000,000 shares of our private restricted common stock, and are issuable to him on June 1 of each year in 2,000,000 portions. We also agreed to reimburse for reasonable and customary business expenses.

On February 29, 2016, we entered into an agreement with an unrelated individual to represent our products to wholesale vendors for a payment of $5,500 per month, payable $3,000 in cash, and $2,500 in shares of our restricted common stock. We also agreed to reimburse him for reasonable and approved business expenses.

7. Subsequent Events

Management has evaluated subsequent events after the balance sheet date, through the issuance of the financial statements, for appropriate accounting and disclosure. Endexx has determined that there were no such events that warrant disclosure or recognition in the financial statements.

Item 6. Describe the Issuer's Business, Products and Services

EXECUTIVE SUMMARY

1- COMPANY PROFILE

Endexx Corporation is a micro-cap, publicly traded company, representing the interest of its shareholders and collaborating with independent software developers, scientists, engineers, and other companies to build businesses that can thrive collectively in the equity markets. Endexx's team recognizes that individually small companies with new technologies have an extremely difficult time sustaining themselves as stand-alone companies. Through our collaborative practices, individual and group skill sets are better utilized to develop technology and grow the business, while centralizing costs and eliminating redundancies.

Endexx is a "Collaboration Corporation" that develops through its subsidiaries cost effective technology solutions for the legal marijuana industry. Endexx's diversified offerings include an easy to use Seed to Sale inventory tracking and process management system for growers, processors, dispensaries, medical patients and users, a high tech commercial grade inventory control dispensing system, a line of superior cannabidiol infused edibles and a pioneering New Jersey consulting firm. Endexx is publicly traded under the symbol EDXC.

The Endexx Management Team and its advisory group each have a wide range of experience, from 10 years in cloud/app development world to decades of experience in the pharmacy industry. The business professionals associated with the direction of the company all have experience growing businesses, developing and implementing new technologies and running publicly traded corporations.

Endexx Corporation is structured to provide a platform for entrepreneurs to thrive, offering maximum return on investment through equity ownership in the parent corporation. Each individual is a shareholder and is encouraged and self-driven to be successful and contribute to the overall objective of increasing shareholder value.

Endexx Corporation is comprised of 5 active divisions:

- M3Hub, a cloud-based medical marijuana inventory tracking and management platform (http://www.m3hub.com/)
- Autospense™, a secure automated inventory control dispensing system
- "Cannsumables", dedicated to the manufacturing and distribution of hemp based CBD-rich nutraceuticals (http://www.cbdunlimited.com/ and http://www.cbdhealthsolutions.com/)
- GreenLeaf Consulting, a medical marijuana consulting company
- Global Solaris Group, a renewable energy and energy management solutions provider for marijuana growers and operators (http://www.gsgsolar.com/)

Other assets include:

Dudad, an advertising app platform under development
Project Canopy, a cloud-based document management, collaboration and storage platform

2- MISSION STATEMENTS

Endexx is the "Collaboration Corporation". Our mission is to harness the power of talented people through technology, the science of management and the spirit of capitalism to create new businesses and foster the growth of the entrepreneurial spirit. Building businesses with recurring revenue streams and high potential for growth in key sectors is our primary objective. Through the collaboration of highly skilled professionals and its subsidiaries, we will build our shareholders significant value.

M3Hub's mission is to integrate through a unified interface connectivity platform as many touch points as possible in the "Seed to Sale" steps and processes that control the marijuana industry and to bring compliance and standardized technology solutions through services and products that are designed to create added value for industry stakeholders, growers, processors, retailers and users.

Autospense's mission is to provide point-of-sale transparency, accountability, tracking, inventory control, and a safe environment for medical and recreational marijuana users to access their medicine. Our dispensing systems are designed to support and facilitate compliance, oversight and standardized solutions through integrated services, while creating added value for retailers and users.

Cannsumables' mission is to develop and distribute the highest quality of hemp based, legally produced, non-psychoactive phytocannabinoids and terpenoids as nutritional supplements for the nutraceutical market, develop advanced formulations and delivery systems that maximize beneficial compounds' bioavailability and health giving properties and promote and support research, case studies and clinical trials to complement existing data and create a universally recognized field of science for non-psychoactive cannabinoids.

Global Solaris Group is dedicated to leveraging the underlying value of each solar or wind project and bring the maximum benefits to our clients. Our mission is to provide renewable energy solutions to marijuana businesses, lower carbon footprint and operating costs and give protection from rising electricity prices.

3- PRODUCTS AND SERVICES

M3 and Autospense™ dispensing technologies provide the necessary solutions and structures to promote compliance with regulation initiatives and full accountability through "Seed to Sale" inventory management and tracking.

A- M3Hub

Legitimizing the entire chain of custody and transaction channel, from seed to sale, grower to client, through the science of management and technology is the basis of the M3HUB Technology solution. The technology solution is based on sound principals derived from the Pharmacy Industry preparing the Medical and recreational Marijuana Industry for real world compliance and laws put in place by the Federal, State and Local Governments.

The M3Hub system tracks and reports all activity from the origin of the seed, to growth, cloning , pesticide, fungicide, fertilization, soil management, replant, gardening, watering, climate control, plant rotation, bud tending, harvesting, drying, processing, testing, packaging, shipping, receiving, and sale to the end user/patient. M3Hub integrates all security and grow room cameras. All human activity is closely monitored and the footage is immediately retrievable at any time. All agricultural processes are monitored and tracked via camera to log and support all aspects of the growing cycles. While the processes are varied and complex, the M3Hub system offers the quickest path to: efficiency, compliance, intuitive supply-chain management and reporting requirements. These features provide support for growers who strive for optimal quality control, yield, growth cycles, strain management and profitability.

M3Hub connectivity platform looks to incorporate multiple service channels including: Financial Solutions, Insurance, Security Monitoring, Vending, Distribution controls, RFID tracking, Taxation Collection Service, POS management, Biometric Protocols, Applications, Doctor Referral and Verification, Centralized Lab Testing, Quality control management and Vending services. The M3Hub system will also foster an outer layer service providing: Referral Networks, Policy and Legal association, Social Media, News and Scientific literature distribution and collective industry affiliation partners.

The M3Hub Seed to Sale platform provides solutions for all necessary aspects and infrastructure for active, reliable, safe, secure, compliance monitoring with access to support a Centralized Medical Marijuana Industry Repository. It segregates privacy and patient protection from product tracking and legal compliance and the handling of Medical and Recreational Marijuana.

Key Applications and Features:

- User Account Management
- Business Definition
- Inventory Management
- Sales Management
- Shipping/Transfer Tracking
- Reporting
- Data Tracking
- Customized Automation
- Regional Data Management
- Point of Sale or Final Transaction Assistance

B- AUTOSPENSE

M3-Autospense™ is a state of the art secure automated inventory control and dispensing system originally developed for managing high value items in industrial settings, i.e., large manufacturing facilities, assembly lines, etc.

The system is customized specifically for the marijuana industry. The machines are manufactured and assembled in Tustin, CA by Autocrib, Inc. (www.autocrib.com)

M3-Autospense™ is a uniquely designed, high-tech automated dispensing system that exceeds industry standards. The software used is specifically designed to properly control transactions and manage inventory. This will significantly improve

profitability, accountability, security and customer satisfaction. M3-Autospense™ is specifically designed and configured to dispense medical marijuana while also managing the supply chain, providing up to the minute accounting details and protecting the security of the product, as well as the patient accessing the system.

Key Features:

- Unmatched product flexibility and security
- Handles wide variety of package sizes and types of items
- Average dispense time under 10 seconds
- Holds 780-1000 unique items or SKUs
- Card reader and thumbprint reader for security
- Dispenses medications, edibles, concentrates and accessories
- Accepts cash and debit cards
- Powerful screen search capability
- Insurable as vault
- High inventory density in very small footprint (34"W x 39"D x 76"H)
- Available for purchase or lease (36 months)

Software Features:

- Dispensary Management Software manages counter, inventory, transfer, ID verification, compliance and reporting
- Displays items pictures
- Displays lab testing data for each item
- Shopping Cart technology for single checkout and payment
- Secure access control for customers and administrators
- Access denial settings based on quantity, prescription, time, date since last issue etc.
- Tracking of item, lot, patient, expiration date with lockout
- Critical item alert
- 174 standard reporting functions
- Reports emailed automatically to PC or tablet for onsite or remote monitory
- Remote maintenance monitoring 24/7

C- CANNSUMABLES

The focus of Cannsumables division is on the development, manufacturing and distribution of nutritional supplements and delivery systems for healthy living, hemp based, using naturally occurring, non psychoactive cannabinoids and terpenoids extracts in the form of infused products for the nutraceutical consumer market.

Delivery systems currently available or under development include vaporizer oils, oral sprays, sublingual drops, popsicles and energy drinks.

Through our relationships with the European Industrial Hemp Association (EHIA), we have built a network of reliable European suppliers of the highest quality hemp extracts and are now able to provide pharmacy grade delivery systems with consistent and precise dosage to be calibrated for a range of conditions. The extracts and finished products are tested at the point of origin and retested in the US for contaminants, trace elements, potency and purity. All products are developed and produced using state of the art GMP facilities and technology that meets or exceeds ISO 9000 standards in collaboration with our distribution partners throughout the US and established licensed medical marijuana manufacturing and processing facilities.

Our product line is establishing a new standard in quality, transparency, consistency and accuracy and creating a uniquely identifiable certification standard and branded seal of quality for the industry. Using state of the art extraction technologies and sustainable cultivation practices, our ultimate goal is to improve the bioavailability of CBD and provide our customers a user-friendly experience and a healthy natural alternative to medication.

4. CONCLUSION

The Medical Marijuana and Recreational Marijuana industry growth rate is on a dramatic upside curve. Sustainability for the Industry requires standardization and reliable compliance methodology. No one company can do everything, rather, an alliance network within the industry collaborating together will assure the longevity and success of this industry in its infancy. Endexx is positioned to become a leader in services and technology solutions for the marijuana industry.

Endexx Corporation (the "Company") was incorporated under the laws of the state of Nevada in September 1997 as Micron Solutions, Inc. In March 2002 the Company changed its name to Panamed Corporation. In 2005 the Company changed its name to Endexx Corporation. The Company's fiscal year ends on September 30th. The Company's primary and secondary SIC codes are: 7380, Miscellaneous Business Services.

Item 7. Describe the issuer's facilities

In June 2013, Endexx Corporation entered into an annual rental/lease agreement for approximately one thousand square feet at 5855 E. Surrey Dr., Cave Creek, AZ. 85331, Suite F. The current rent is $1,500 per month.

Item 8. Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons

Todd Davis – President, Chief Executive Officer, Chief Financial Officer and Sole Director

Todd Davis has served as our Chief Executive Officer, Chief Financial Officer and Director since 2003.

TODD A. DAVIS CV
Current Address:
37043 North Kohuana Place
Cave Creek, AZ. 85331

Curriculum Vitae

Date of Birth:	August 15, 1966
Birth Place:	Phoenix, Arizona
Education:	Bachelor of Science: Administrative Communications (Business/Communications) Northern Arizona University: Graduated May 1989 Master's Studies: Arizona State University (International Finance/Management)
Executive:	Chief Executive Officer and COB Endexx Corporation 2003-Present: A diversified small cap growth company, incubating and fostering growth through Collaboration. (EDXC)
Professional:	Series 7/63 licenses 1990-2001: Investment Banker/Stockbroker 1990-1995: Small and Microcap Specialist: Participated in over 100 IPOs, Secondary Offerings, and Private Placements Stockbroker/Trading Analyst 1995-2000: Developed Proprietary trading system and analysis for high performance ROI. I employed the system with retail investors and institutional traders over multiple platforms. Independence (2000-Present): Consultant for CEOs of public corporations. I provide a proprietary system to enhance CEO performance in market cap valuations and metrics. Owner of rock quarry, 2005-present. I have served as Founder, Director, Investor and operator of more than ten publicly traded Corporations 2000-Present. Founder, Designer, and Proprietor of Pro17.com 2008-present. A high Alpha, trading and decision making platform designed to forecast any stock, ETF, Index or commodity in increments of 17 day trading cycles without bias. It has achieved 87-91% accuracy over 5 years and 1000 plus equities averaging over 10% profit per trade.
Family:	Married 7 years. Five kids ranging in age from 6-22.

B. Legal/Disciplinary History.

None of the issuer's officers, directors or control persons has, within the last five years, been subject to any conviction, order, judgment, decree, or finding required to be disclosed by the OTC Markets Guidelines for Providing Adequate Current Information.

C. Beneficial Shareholders.

Rayne Forecast Inc.; Todd Davis
Rayne Forecast Inc. ("Rayne") owns 53,247,477 shares of the Company, and Rayne is wholly owned by the Company's CEO and sole director, Todd Davis. Rayne is located at 37043 N. Kohuana Pl., Cave Creek, AZ 85331, and its resident agent is Thomas A. Dwyer & Associates, Inc. located at 401 S. La Salle St., Chicago, Illinois 60605.

Item 9. Third Party Providers

1. Legal Counsel:

Law Offices of Gary L. Blum
3278 Wilshire Blvd., Suite 603
Los Angeles, CA 90010
Phone: 213.381.7450
Email: gblum@gblumlaw.com

2. Accountant or Auditor:

Ed Steinback
Steinback & Associates
7760 E State Route 69
Prescott Valley, AZ 86314
Phone: 928.772.7082
Email: steinbacke@yahoo.com

3. Investor Relations Consultant:

Irth Communications LLC.
(310) 425-3315

Item 10. Issuer Certification

I, Todd Davis, President, Chief Executive Officer, and Chief Financial Officer, certify that:

1. I have reviewed this Interim Quarterly Disclosure Statement of Endexx Corporation and its subsidiaries;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 15, 2016

By: /s/ Todd Davis
Todd Davis,
President, Chief Executive Officer, Chief Financial Officer